

# Overview of Relevant Codes

## ■ INDICATIONS<sup>1</sup>

RINVOQ is indicated for the treatment of:

- **Moderately to severely active rheumatoid arthritis (RA)** in adults who have had an inadequate response or intolerance to one or more tumor necrosis factor (TNF) blockers.
- **Active ankylosing spondylitis (AS)** in adults who have had an inadequate response or intolerance to one or more TNF blockers.
- **Active non-radiographic axial spondyloarthritis (nr-axSpA)** with objective signs of inflammation in adults who have had an inadequate response or intolerance to TNF blocker therapy.
- **Giant cell arteritis (GCA)** in adults.

**Limitations of Use:** RINVOQ is not recommended for use in combination with other Janus kinase (JAK) inhibitors, biologic disease-modifying antirheumatic drugs (bDMARDs), or with potent immunosuppressants such as azathioprine and cyclosporine.

- **Refractory, moderate to severe atopic dermatitis (AD)** in adults and pediatric patients 12 years of age and older whose disease is not adequately controlled with other systemic drug products, including biologics, or when use of those therapies is inadvisable.

**Limitations of Use:** RINVOQ is not recommended for use in combination with other JAK inhibitors, biologic immunomodulators, or other immunosuppressants.

- **Moderately to severely active ulcerative colitis (UC)** in adults who have had an inadequate response or intolerance to one or more TNF blockers.
- **Moderately to severely active Crohn's disease (CD)** in adults who have had an inadequate response or intolerance to one or more TNF blockers.

**Limitations of Use:** RINVOQ is not recommended for use in combination with other JAK inhibitors, biological therapies for ulcerative colitis or Crohn's disease, or with potent immunosuppressants such as azathioprine and cyclosporine.

RINVOQ/RINVOQ LQ is indicated for the treatment of:

- **Active psoriatic arthritis (PsA)** in adults and pediatric patients 2 years of age and older who have had an inadequate response or intolerance to one or more TNF blockers.
- **Active polyarticular juvenile idiopathic arthritis (pJIA)** in patients 2 years of age and older who have had an inadequate response or intolerance to one or more TNF blockers.

Please see additional Important Safety Information, including **BOXED WARNING** on Serious Infections, Mortality, Malignancies, Major Adverse Cardiovascular Events, and Thrombosis, on pages 4 and 5.

Please click [here](#) for full Prescribing Information.

**Limitations of Use:** RINVOQ/RINVOQ LQ is not recommended for use in combination with other JAK inhibitors, bDMARDs, or with potent immunosuppressants such as azathioprine and cyclosporine.

## ■ SAFETY CONSIDERATIONS FOR RINVOQ/RINVOQ LQ (upadacitinib)<sup>1</sup>

**SERIOUS INFECTIONS:** Patients treated with RINVOQ\* are at increased risk of serious bacterial (including tuberculosis [TB]), fungal, viral, and opportunistic infections leading to hospitalization or death. Most patients who developed these infections were taking concomitant immunosuppressants, such as methotrexate or corticosteroids.

**MORTALITY:** A higher rate of all-cause mortality, including sudden cardiovascular (CV) death, was observed with a Janus kinase inhibitor (JAKi) in a study comparing another JAKi with tumor necrosis factor (TNF) blockers in rheumatoid arthritis (RA) patients ≥50 years with ≥1 CV risk factor.

**MALIGNANCIES:** Malignancies have occurred in RINVOQ-treated patients. A higher rate of lymphomas and lung cancer (in current or past smokers) was observed with another JAKi when compared with TNF blockers in RA patients.

**MAJOR ADVERSE CARDIOVASCULAR EVENTS:** A higher rate of CV death, myocardial infarction, and stroke was observed with a JAKi in a study comparing another JAKi with TNF blockers in RA patients ≥50 years with ≥1 CV risk factor. History of smoking increases risk.

**THROMBOSES:** Deep venous thrombosis, pulmonary embolism, and arterial thrombosis have occurred in patients treated for inflammatory conditions with JAK inhibitors, including RINVOQ. A higher rate of thrombosis was observed with another JAKi when compared with TNF blockers in RA patients.

**HYPERSENSITIVITY:** RINVOQ is contraindicated in patients with hypersensitivity to RINVOQ or its excipients.

**OTHER SERIOUS ADVERSE REACTIONS:**

Hypersensitivity Reactions, Gastrointestinal Perforations, Laboratory Abnormalities, and Embryo-Fetal Toxicity.

\*Unless otherwise stated, "RINVOQ" in the SAFETY CONSIDERATIONS refers to RINVOQ and RINVOQ LQ.



# Overview of relevant codes

ICD-10-CM diagnosis codes<sup>2\*</sup>

## Rheumatoid arthritis

Code	Description
M05.6-M05.69	Rheumatoid arthritis with involvement of other organs and systems
M05.7-M05.9	Rheumatoid arthritis with rheumatoid factor
M06.0-M06.0A	Rheumatoid arthritis without rheumatoid factor

## Giant cell arteritis

Code	Description
M31.5	Giant cell arteritis with polymyalgia rheumatica
M31.6	Other giant cell arteritis

## Psoriatic arthritis

Code	Description
L40.50	Arthropathic psoriasis, unspecified
L40.51	Distal interphalangeal psoriatic arthropathy
L40.54	Psoriatic juvenile arthropathy
L40.59	Other psoriatic arthropathy

## Ankylosing spondylitis

Code	Description
M45.0-M45.9	Ankylosing spondylitis

## Non-radiographic axial spondyloarthritis

Code	Description
M45.A (M45.A0-AB)	Non-radiographic axial spondyloarthritis

\*The codes shown are only suggestions and may vary by patient.

This information is presented for informational purposes only and is not intended to provide reimbursement or legal advice. The information presented here does not guarantee payment or coverage. Providers are encouraged to contact third-party payers for specific information about their coverage policies.

ICD-10-CM, International Classification of Diseases, Tenth Revision, Clinical Modification.

## SAFETY CONSIDERATIONS FOR RINVOQ/RINVOQ LQ (upadacitinib)<sup>1</sup>

**SERIOUS INFECTIONS:** Patients treated with RINVOQ<sup>\*</sup> are at increased risk of serious bacterial (including tuberculosis [TB]), fungal, viral, and opportunistic infections leading to hospitalization or death. Most patients who developed these infections were taking concomitant immunosuppressants, such as methotrexate or corticosteroids.

**MORTALITY:** A higher rate of all-cause mortality, including sudden cardiovascular (CV) death, was observed with a Janus kinase inhibitor (JAKi) in a study comparing another JAKi with tumor necrosis factor (TNF) blockers in rheumatoid arthritis (RA) patients ≥50 years with ≥1 CV risk factor.

**MALIGNANCIES:** Malignancies have occurred in RINVOQ-treated patients. A higher rate of lymphomas and lung cancer (in current or past smokers) was

Please see additional Important Safety Information, including **BOXED WARNING** on Serious Infections, Mortality, Malignancies, Major Adverse Cardiovascular Events, and Thrombosis, on pages 4 and 5.

Please click here for full [Prescribing Information](#).

## Polyarticular juvenile idiopathic arthritis

Code	Description
M08.00-M08.0A	Unspecified juvenile rheumatoid arthritis
M08.20-M08.2A	Juvenile rheumatoid arthritis with systemic onset
M08.8	Other juvenile arthritis

## Atopic dermatitis

Code	Description
L20.8-L20.9	Atopic dermatitis

## Crohn's disease

Code	Description
K50.0-K50.019	Crohn's disease of small intestine
K50.1-K50.119	Crohn's disease of large intestine
K50.8-K50.819	Crohn's disease of both small and large intestine
K50.9-K50.919	Crohn's disease, unspecified

## Ulcerative colitis

Code	Description
K51.0-K51.019	Ulcerative pancolitis
K51.2-K51.219	Ulcerative proctitis
K51.3-K51.319	Ulcerative rectosigmoiditis
K51.4-K51.419	Inflammatory polyps of colon
K51.5-K51.519	Left sided colitis
K51.8-K51.919	Other ulcerative colitis or unspecified

observed with another JAKi when compared with TNF blockers in RA patients.

**MAJOR ADVERSE CARDIOVASCULAR EVENTS:** A higher rate of CV death, myocardial infarction, and stroke was observed with a JAKi in a study comparing another JAKi with TNF blockers in RA patients ≥50 years with ≥1 CV risk factor. History of smoking increases risk.

**THROMBOSES:** Deep venous thrombosis, pulmonary embolism, and arterial thrombosis have occurred in patients treated for inflammatory conditions with JAK inhibitors, including RINVOQ. A higher rate of thrombosis was observed with another JAKi when compared with TNF blockers in RA patients.

**HYPERSENSITIVITY:** RINVOQ is contraindicated in patients with hypersensitivity to RINVOQ or its excipients.

**OTHER SERIOUS ADVERSE REACTIONS:** Hypersensitivity Reactions, Gastrointestinal Perforations, Laboratory Abnormalities, and Embryo-Fetal Toxicity.

\*Unless otherwise stated, "RINVOQ" in the SAFETY CONSIDERATIONS refers to RINVOQ and RINVOQ LQ.

# National Drug Codes (NDC)

Electronic data exchange standards usually require the use of an 11-digit NDC. To convert a 10-digit NDC to an 11-digit NDC, a leading zero is added within the sequence of numbers (in the case of RINVOQ, a 0 is added in front of 0074 to create 00074). If it is not already included, you may need to add the NDC to your EMR system for e-prescribing. Check with the payer to confirm the correct code required when billing for RINVOQ.

RINVOQ dosage <sup>1</sup>	10-digit NDC <sup>1</sup>	11-digit NDC <sup>1</sup>
15 mg extended-release tablets	0074-2306-30	00074-2306-30
30 mg extended-release tablets	0074-2310-30	00074-2310-30
45 mg extended-release tablets	0074-1043-28	00074-1043-28
1 mg/mL oral solution	0074-2320-01	00074-2320-01



## For additional guidance

For additional guidance on coding, please refer to the Department of Health and Human Services Evaluation and Management Services guide available at [www.cms.gov](http://www.cms.gov)



## Support

For case-specific or general access support, call your **Field Reimbursement Manager**, or call **1.877.COMPLETE** (1.877.266.7538)

EMR, electronic medical record.

## SAFETY CONSIDERATIONS FOR RINVOQ/RINVOQ LQ (upadacitinib)<sup>1</sup>

**SERIOUS INFECTIONS:** Patients treated with RINVOQ<sup>\*</sup> are at increased risk of serious bacterial (including tuberculosis [TB]), fungal, viral, and opportunistic infections leading to hospitalization or death. Most patients who developed these infections were taking concomitant immunosuppressants, such as methotrexate or corticosteroids.

**MORTALITY:** A higher rate of all-cause mortality, including sudden cardiovascular (CV) death, was observed with a Janus kinase inhibitor (JAKi) in a study comparing another JAKi with tumor necrosis factor (TNF) blockers in rheumatoid arthritis (RA) patients ≥50 years with ≥1 CV risk factor.

**MALIGNANCIES:** Malignancies have occurred in RINVOQ-treated patients. A higher rate of lymphomas and lung cancer (in current or past smokers) was observed with another JAKi when compared with TNF blockers in RA patients.

**MAJOR ADVERSE CARDIOVASCULAR EVENTS:** A higher rate of CV death, myocardial infarction, and stroke was observed with a JAKi in a study comparing another JAKi with TNF blockers in RA patients ≥50 years with ≥1 CV risk factor. History of smoking increases risk.

**THROMBOSES:** Deep venous thrombosis, pulmonary embolism, and arterial thrombosis have occurred in patients treated for inflammatory conditions with JAK inhibitors, including RINVOQ. A higher rate of thrombosis was observed with another JAKi when compared with TNF blockers in RA patients.

**HYPERSENSITIVITY:** RINVOQ is contraindicated in patients with hypersensitivity to RINVOQ or its excipients.

### OTHER SERIOUS ADVERSE REACTIONS:

Hypersensitivity Reactions, Gastrointestinal Perforations, Laboratory Abnormalities, and Embryo-Fetal Toxicity.

<sup>\*</sup>Unless otherwise stated, "RINVOQ" in the SAFETY CONSIDERATIONS refers to RINVOQ and RINVOQ LQ.

Please see additional Important Safety Information, including **BOXED WARNING** on Serious Infections, Mortality, Malignancies, Major Adverse Cardiovascular Events, and Thrombosis, on pages 4 and 5.

Please click [here](#) for full Prescribing Information.



# **IMPORTANT SAFETY INFORMATION FOR RINVOQ<sup>®</sup> (upadacitinib)<sup>1</sup>**

## **■ IMPORTANT SAFETY INFORMATION FOR RINVOQ/ RINVOQ LQ (upadacitinib)**

### **SERIOUS INFECTIONS**

Patients treated with RINVOQ<sup>\*</sup> are at increased risk for developing serious infections that may lead to hospitalization or death. Most patients who developed these infections were taking concomitant immunosuppressants, such as methotrexate or corticosteroids. If a serious infection develops, interrupt RINVOQ until the infection is controlled.

Reported infections include:

- Active tuberculosis (TB), which may present with pulmonary or extrapulmonary disease. Test patients for latent TB before RINVOQ use and during therapy. Consider treatment for latent TB infection prior to RINVOQ use.
- Invasive fungal infections, including cryptococcosis and pneumocystosis.
- Bacterial, viral, including herpes zoster, and other infections due to opportunistic pathogens.

Carefully consider the risks and benefits of treatment with RINVOQ prior to initiating therapy in patients with chronic or recurrent infection. Monitor patients closely for the development of signs and symptoms of infection during and after treatment with RINVOQ, including the possible development of TB in patients who tested negative for latent TB infection prior to initiating therapy.

### **MORTALITY**

In a large, randomized, postmarketing safety study comparing another Janus kinase (JAK) inhibitor with tumor necrosis factor (TNF) blockers in rheumatoid arthritis (RA) patients  $\geq 50$  years old with at least one cardiovascular (CV) risk factor, a higher rate of all-cause mortality, including sudden CV death, was observed with the JAK inhibitor. Consider the benefits and risks for the individual patient prior to initiating or continuing therapy with RINVOQ.

### **MALIGNANCIES**

Lymphoma and other malignancies have been observed in patients treated with RINVOQ.

In a large, randomized, postmarketing safety study comparing another JAK inhibitor with TNF blockers in RA patients, a higher rate of malignancies (excluding non-melanoma skin cancer [NMSC]), lymphomas, and lung cancer (in current or past smokers) was observed with the JAK inhibitor. Patients who are current or past smokers are at additional increased risk.

With RINVOQ, consider the benefits and risks for the individual patient prior to initiating or continuing therapy, particularly in patients with a known malignancy (other than a successfully treated NMSC), patients who develop a malignancy when on treatment, and patients who are current or past smokers. NMSCs have been reported in

patients treated with RINVOQ. Periodic skin examination is recommended for patients who are at increased risk for skin cancer. Advise patients to limit sunlight exposure by wearing protective clothing and using sunscreen.

### **MAJOR ADVERSE CARDIOVASCULAR EVENTS (MACE)**

In a large, randomized, postmarketing study comparing another JAK inhibitor with TNF blockers in RA patients  $\geq 50$  years old with at least one CV risk factor, a higher rate of MACE (defined as cardiovascular death, myocardial infarction, and stroke) was observed with the JAK inhibitor. Patients who are current or past smokers are at additional increased risk. Discontinue RINVOQ in patients that have experienced a myocardial infarction or stroke.

Consider the benefits and risks for the individual patient prior to initiating or continuing therapy with RINVOQ, particularly in patients who are current or past smokers and patients with other CV risk factors. Patients should be informed about the symptoms of serious CV events and the steps to take if they occur.

### **THROMBOSIS**

Thromboses, including deep venous thrombosis, pulmonary embolism, and arterial thrombosis, have occurred in patients treated for inflammatory conditions with JAK inhibitors, including RINVOQ. Many of these adverse events were serious and some resulted in death. In a large, randomized, postmarketing study comparing another JAK inhibitor to TNF blockers in RA patients  $\geq 50$  years old with at least one CV risk factor, a higher rate of thrombosis was observed with the JAK inhibitor. Avoid RINVOQ in patients at risk. Patients with symptoms of thrombosis should discontinue RINVOQ and be promptly evaluated.

### **HYPERSENSITIVITY**

RINVOQ is **contraindicated** in patients with known hypersensitivity to upadacitinib or any of its excipients. Serious hypersensitivity reactions, such as anaphylaxis and angioedema, were reported in patients receiving RINVOQ in clinical trials. If a clinically significant hypersensitivity reaction occurs, discontinue RINVOQ and institute appropriate therapy.

### **GASTROINTESTINAL PERFORATIONS**

Gastrointestinal (GI) perforations have been reported in clinical trials with RINVOQ. Monitor RINVOQ-treated patients who may be at risk for GI perforation (e.g., patients with a history of diverticulitis and patients taking NSAIDs or corticosteroids). Promptly evaluate patients presenting with new onset abdominal pain for early identification of GI perforation.

Please see additional Important Safety Information, continued on page 5.

Please click [here](#) for full Prescribing Information.





# **IMPORTANT SAFETY INFORMATION FOR RINVOQ<sup>®</sup> (upadacitinib)<sup>1</sup> (CONTINUED)**

## **LABORATORY ABNORMALITIES**

### **Neutropenia**

Treatment with RINVOQ was associated with an increased incidence of neutropenia (absolute neutrophil count [ANC] <1000 cells/mm<sup>3</sup>). Treatment with RINVOQ is not recommended in patients with an ANC <1000 cells/mm<sup>3</sup>. Evaluate neutrophil counts at baseline and thereafter according to routine patient management.

### **Lymphopenia**

Absolute lymphocyte counts (ALC) <500 cells/mm<sup>3</sup> were reported in RINVOQ-treated patients. Treatment with RINVOQ is not recommended in patients with an ALC <500 cells/mm<sup>3</sup>. Evaluate at baseline and thereafter according to routine patient management.

### **Anemia**

Decreases in hemoglobin levels to <8 g/dL were reported in RINVOQ-treated patients. Treatment should not be initiated or should be interrupted in patients with hemoglobin levels <8 g/dL. Evaluate at baseline and thereafter according to routine patient management.

### **Lipids**

Treatment with RINVOQ was associated with increases in lipid parameters, including total cholesterol, low-density lipoprotein (LDL) cholesterol, and high-density lipoprotein (HDL) cholesterol. Manage patients according to clinical guidelines for the management of hyperlipidemia. Evaluate patients 12 weeks after initiation of treatment and thereafter according to the clinical guidelines for hyperlipidemia.

### **Liver enzyme elevations**

Treatment with RINVOQ was associated with increased incidence of liver enzyme elevation compared to placebo. Evaluate at baseline and thereafter according to routine patient management. Prompt investigation of the cause of liver enzyme elevation is recommended to identify potential cases of drug-induced liver injury. If increases in aspartate aminotransferase (AST) or alanine aminotransferase (ALT) are observed during routine patient management and drug-induced liver injury is suspected, RINVOQ should be interrupted until this diagnosis is excluded.

## **EMBRYO-FETAL TOXICITY**

Based on findings in animal studies, RINVOQ may cause fetal harm when administered to a pregnant woman. Advise pregnant women of the potential risk to a fetus. Advise females of reproductive potential to use effective contraception during treatment with RINVOQ and for 4 weeks after the final dose. Verify pregnancy status of females of reproductive potential prior to starting treatment with RINVOQ.

## **VACCINATION**

Avoid use of live vaccines during, or immediately prior to, RINVOQ therapy. Prior to initiating RINVOQ, patients should be brought up to date on all immunizations, including prophylactic varicella zoster or herpes zoster vaccinations, in agreement with current immunization guidelines.

## **MEDICATION RESIDUE IN STOOL**

Reports of medication residue in stool or ostomy output have occurred in patients taking RINVOQ. Most reports described anatomic or functional GI conditions with shortened GI transit times. Instruct patients to contact their healthcare provider if medication residue is observed repeatedly. Monitor patients clinically and consider alternative treatment if there is an inadequate therapeutic response.

## **LACTATION**

There are no data on the presence of RINVOQ in human milk, the effects on the breastfed infant, or the effects on milk production. Available data in animals have shown the excretion of RINVOQ in milk. Advise patients that breastfeeding is not recommended during treatment with RINVOQ and for 6 days after the last dose.

## **HEPATIC IMPAIRMENT**

RINVOQ is not recommended for use in patients with severe hepatic impairment.

## **ADVERSE REACTIONS**

The most common adverse reactions in RINVOQ clinical trials were upper respiratory tract infections, herpes zoster, herpes simplex, bronchitis, nausea, cough, pyrexia, acne, headache, peripheral edema, increased blood creatine phosphokinase, hypersensitivity, folliculitis, abdominal pain, increased weight, influenza, fatigue, neutropenia, myalgia, influenza-like illness, elevated liver enzymes, rash, and anemia.

Inform patients that retinal detachment has been reported in clinical trials with RINVOQ. Advise patients to immediately inform their healthcare provider if they develop any sudden changes in vision while receiving RINVOQ.

**Dosage Forms and Strengths:** RINVOQ is available in 15 mg, 30 mg, and 45 mg extended-release tablets. RINVOQ LQ is available in a 1 mg/mL oral solution.

\*Unless otherwise stated, "RINVOQ" in the IMPORTANT SAFETY INFORMATION refers to RINVOQ and RINVOQ LQ.

**References:** 1. RINVOQ [package insert]. North Chicago, IL: AbbVie Inc. 2. ICD-10-CM tabular list of diseases and injuries. Centers for Disease Control and Prevention website. Updated February 1, 2024. Accessed April 4, 2024. <https://www.cms.gov/files/zip/2024-code-tables-tabular-and-index-updated-02/01/2024.zip>

Please click here for full [Prescribing Information](#), including **BOXED WARNING**.

abbvie

© 2025 AbbVie. All rights reserved.  
RINVOQ<sup>®</sup> and its design are registered trademarks of AbbVie Biotechnology Ltd.  
US-RNQR-2500085 April 2025

